Nórsko -
nórčina -
Statens legemiddelverk
norspan 20 mikrog/ time
mundipharma as - buprenorfin - depotplaster - 20 mikrog/ time
Nórsko -
nórčina -
Statens legemiddelverk
norspan 5 mikrog/ time
mundipharma as - buprenorfin - depotplaster - 5 mikrog/ time
Nórsko -
nórčina -
Statens legemiddelverk
norspan 10 mikrog/ time
mundipharma as - buprenorfin - depotplaster - 10 mikrog/ time
Nórsko -
nórčina -
Statens legemiddelverk
norspan 15 mikrog/ time
mundipharma as - buprenorfin - depotplaster - 15 mikrog/ time
Nórsko -
nórčina -
Statens legemiddelverk
norspan 30 mikrog/ time
mundipharma as - buprenorfin - depotplaster - 30 mikrog/ time
Nórsko -
nórčina -
Statens legemiddelverk
bugnanto 15 mikrog/ time
sandoz - københavn - buprenorfin - depotplaster - 15 mikrog/ time
Európska únia -
nórčina -
EMA (European Medicines Agency)
nubeqa
bayer ag - darolutamide - prostatic neoplasmer, kastrering-resistant - endokrin terapi - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.
Nórsko -
nórčina -
Statens legemiddelverk
buprefarm 15 mikrog/ time
orifarm generics a/s - buprenorfin - depotplaster - 15 mikrog/ time
Nórsko -
nórčina -
Statens legemiddelverk
buprefarm 30 mikrog/ time
orifarm generics a/s - buprenorfin - depotplaster - 30 mikrog/ time
Nórsko -
nórčina -
Statens legemiddelverk
bugnanto 5 mikrog/ time
sandoz - københavn - buprenorfin - depotplaster - 5 mikrog/ time